Siena and Rosia

over a century of innovation

1904

Foundation of the Institute

In a small villa on the outskirts of Siena, Achille Sclavo founds the Institute, to produce the serum against anthrax he had discovered.

More

1910-20

The industrial development

The Sclavo Institute is restructured to meet the scientific advances of the time and the needs of World War I.

More

1930-40

Sclavo’s legacy

After the death of the founder, the Institute remained a family business, gradually establishing itself at the national level.

More

1950

The international scope and new applications

The increasing degree of technical sophistication leads the Institute to be a modern center not only of production, but also for the study and research.

More

1960

Albert Sabin’s turning point

The Institute begins to produce Sabin’s anti-polio and starts the collaboration with the Wellcome Foundation in London.

More

1970-80

Expansion of the institute

The Institute extends in the US, while the futuristic Research Center is born and the activities of the new area of Rosia start.

More

1990

The genetics revolution

From the collaboration with Venter, the Reverse Vaccinology technique is born, key of the vaccine against meningococcus B.

More

2000

The fight against meningitis and flu

The company becomes one of the most important realities in vaccines, whose study proceeds, in addition to their use in mass vaccinations.

More

Today

Number one in vaccines

With the integration in GSK, the Siena and Rosia site becomes part of a pharmaceutical company committed on a global scale.

More

 
chiudi

Today

Number one in vaccines


With the integration in GSK, the Siena and Rosia site becomes part of a pharmaceutical company committed on a global scale.

SCLAVO23

– The current building of Research Center in Siena –

With the integration in GSK, the Siena and Rosia site becomes part of a global healthcare company committed in research and develop a broad range of innovative products in pharmaceutical, vaccines and consumer healthcare, and maximising access to them delivers direct benefit to patients and consumers.

| Materiale d’archivio gentilmente concesso da Gruppo Anziani Sclavo |